



Archit Organosys Limited

25/9/A,25/9/B, Phase III, G.I.D.C
Naroda, Ahmedabad-382330. Gujarat, INDIA.

Phone : +91-79-22821154, 22800785

CIN : L24110GJ1993PLC019941

Date: June 14, 2021

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street, Mumbai - 400 001.

Dear Sir/Madam,

Sub.: Statement of Deviation in utilization of funds raised through Preferential Convertible warrant as required under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

With reference to the captioned subject matter, attached herewith the details of utilization of funds till 31st March, 2021.

Kindly acknowledge the receipt of the same.

For Archit Organosys Limited



Kandarp Amin
Chairman & Whole Time Director

CORPORATE OFFICE : 9th Floor, Venus Benecia, Nr. Pakwan Restaurant, Bodakdev, S.G. Highway, Ahmedabad-380054. Gujarat, INDIA.
Phone : +91-79-26873340 / 48925370

UNIT-II : Survey no 228/A, Paiki 7, Paiki 2, Village - Narmad, Bhavnagar-364313. Gujarat, INDIA.

E-MAIL : sales@architorg.com | export@architorg.com | share@architorg.com | trading@architorg.com • **Website :** www.architorg.com

Statement of Deviation / Variation in utilization of funds raised

Name of listed entity	Archit Organosys Limited
Mode of Fund Raising	Preferential issue of Convertible Warrants
Date of Raising Funds	13/10/2020
Amount Raised	<p>Issued size of Rs. 550 lakh (55,00,000 number of warrants of Rs. 10 each). Upon application, total Rs. 137.5 lakh being 25% of issue price of warrants has been received as per SEBI (ICDR) Regulations.</p> <p>The balance money is receivable at the time of conversion of warrants into equity shares.</p>
Report filed for Quarter ended	31 st March, 2021
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	-
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	-
If Yes, Date of shareholder Approval	-
Explanation for the Deviation / Variation	-
Comments of the Audit Committee after review	-
Comments of the auditors, if any	-
Objects for which funds have been raised and where there has been a deviation, in the following table	



Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/ Variation for the quarter according to applicable object	Remarks if any
<p>The proceeds of the proposed issue will be utilized for any one or in combination with any one or more of the purposes such as to augment the fund for to augment the net worth of the Company and to form a capital base for business growth, to meet the long term fund requirements of the Company, to repay the debt of the Company for capital expenditure to be incurred for expansion and new product addition, to meet working capital requirements arose due to loss, to improve the capital structure and for general corporate purpose.</p>	<p>N.A.</p>	<p>Issue Size: Rs. 550 Lakh Amount received: Rs. 137.5 Lakh</p>	<p>N.A</p>	<p>Rs. 137.5 Lakh</p>	<p>N.A</p>	<p>Amount is received as per SEBI (ICDR) Regulations, 25% of issue price i.e. Rs. 2.5 per warrant has been received at the time of application of warrants. The balance money is receivable at the time of conversion of warrants into equity shares. These details are as on 31/03/2021 hence the effect of balance Rs. 7.50 per share received for allotment of 20,00,000 equity shares upon conversion of warrants has not mentioned.</p>

Date: 14/06/2021

Kandarp Amin

**Kandarp Amin
Chairman and Whole Time
Director**

